Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEN1571 Phase 1 in Advanced Solid Tumors
NCT05377528Phase 1Completed
- Sponsor
- Agenus Inc.
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AGEN1571 in solid tumor (5 arms), sponsored by Agenus Inc. Primary endpoints: Number Of Participants With Dose-limiting Toxicities and Number Of Participants With Treatment-emergent Adverse Events. Started Jul 2022; status: completed.
02
Drugs
AGEN1571
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05377528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377528.